FindTrial
Sign In

CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01540604
Enrollment
Unknown
Registered
2012-02-29
Start date
Unknown
Completion date
Unknown
Last updated
2012-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Becker Muscular Dystrophy, Duchenne Muscular Dystrophy

Keywords

DMD, BMD, symptomatic carriers

Brief summary

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

Interventions

DRUGCRD007

Sponsors

RSPR Pharma AB
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
2 Years to 11 Years

Inclusion criteria

* Documented diagnosis of dystrophinopathy

Exclusion criteria

* Severe functional impairment

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026